| Autor: |
Yamagata, Yutaka, Yuasa, Yumi, Yamamoto, Kazumichi, Okamoto, Kayoko, Igari, Yasutaka, Iga, Katsumi, Ogawa, Yasuaki |
| Zdroj: |
Journal of Interferon & Cytokine Research; February 1, 2000, Vol. 20 Issue: 2 p153-160, 8p |
| Abstrakt: |
The objective of this study was to assess the pharmacologic effect of continuously released recombinant human interferon-alpha (rHuIFN-alpha) in the liver, the target organ of chronic hepatitis B and C, using 2',5'-oligoadenylate synthetase (2',5'-OAS) activity as an indicator of an antiviral state. A cylindrical matrix prepared from tetraglycerol dipalmitate (TGDP), a polyglycerol ester of fatty acids (PGEF), released rHuIFN-alpha in a pseudo-zero-order manner for about 1 week after implantation into mice, without any major loss of rHuIFN alpha biologic activity during the release period. To evaluate the pharmacologic effect of the rHuIFN-alpha continuously released from this type of matrix, we established a murine test system. Bolus injections of rHuIFN-alpha solution at three doses increased 2',5'-OAS activities in murine liver extract and serum in a dose-dependent manner, indicating that this system is suitable for evaluating rHuIFN-alpha activity. After subcutaneous insertion of TGDP-matrix implants containing 5.5 X 107 IU rHuIFN-alpha per animal, 2',5'-OAS activities in both liver extracts and serum increased rapidly and remained high for over 1 week. Subcutaneous injections of an equivalent total dose (5.0 X 107 IU/animal per week) of rHuIFN-alpha solution in three or seven fractions prolonged 2',5'-OAS activities compared with a single bolus injection. Comparing 2',5'-OAS activity on day 7 and the portion of the area under the 2',5'-OAS activity-time curve above the normal level (DeltaAUC) between the TGDP-matrix implant and multiple injections of the solution revealed that continuously released rHuIFN alpha has an effect almost equivalent to that of three or seven injections of the solution per week. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
